# Tris Pharma
Tris Pharma, Inc. is a privately held, commercial-stage pharmaceutical company headquartered at 2033 Route 130 in Monmouth Junction, New Jersey, that develops and markets branded and specialty generic medicines, with a marketed ADHD portfolio built on its proprietary LiquiXR extended-release liquid technology and a growing pain and central nervous system (CNS) pipeline.[1](https://www.sec.gov/Archives/edgar/data/1754826/0001754826-18-000003.txt) • [2](https://www.globenewswire.com/news-release/2026/07/09/3324711/0/en/Tris-Pharma-Launches-Adneuris-Therapeutics-to-Advance-a-New-Era-in-Pain-Medicine.html) The company is led by founder and CEO Ketan Mehta and remains private and operating as of mid-2026.[3](https://staging.trispharma.com/who-we-are/leadership/)
| Key fact | Detail |
| --- | --- |
| Legal name and headquarters | Tris Pharma, Inc., a New Jersey corporation at 2033 Route 130, Monmouth Junction, NJ 08852[1](https://www.sec.gov/Archives/edgar/data/1754826/0001754826-18-000003.txt) |
| Sector | Pharmaceuticals: branded ADHD products and specialty generics[1](https://www.sec.gov/Archives/edgar/data/1754826/0001754826-18-000003.txt) • [4](https://www.sec.gov/Archives/edgar/data/1474835/000165495420003539/ex450.htm) |
| Founder and CEO | Ketan Mehta, a pharmacist with an MS in Pharmaceutical Sciences from the University of Oklahoma[3](https://staging.trispharma.com/who-we-are/leadership/) |
| Other filed officers | Peter Ciano (executive officer) and Smita Mehta (director), per the September 2018 Form D[1](https://www.sec.gov/Archives/edgar/data/1754826/0001754826-18-000003.txt) |
| Financing | $125,000,000 reported sold in a Form D dated September 21, 2018[1](https://www.sec.gov/Archives/edgar/data/1754826/0001754826-18-000003.txt) |
| Marketed ADHD products | DYANAVEL XR (amphetamine), Quillivant XR, and QuilliChew ER (methylphenidate HCl), CNS stimulants for ADHD in people 6 years and older[5](https://www.trisadhd.com/) |
| Status (2026) | Privately held and operating; launched pain-focused subsidiary Adneuris Therapeutics in July 2026[2](https://www.globenewswire.com/news-release/2026/07/09/3324711/0/en/Tris-Pharma-Launches-Adneuris-Therapeutics-to-Advance-a-New-Era-in-Pain-Medicine.html) |
## History and founding
[Ketan Mehta](https://www.edgepedia.org/ketan-mehta) founded Tris Pharma and serves as its President and CEO. According to the company's leadership page, before founding Tris he worked for Capsugel, formerly a division of Pfizer, in sales, marketing, and business development for eight years, and previously worked as a pharmaceutical scientist; he holds an MS in Pharmaceutical Sciences from the [University of Oklahoma](https://www.edgepedia.org/university-of-oklahoma).[3](https://staging.trispharma.com/who-we-are/leadership/) Directory profiles record a founding year of 2000, but no primary or journalistic source in the public record states it, so the year should be treated as unverified.[6](https://pitchbook.com/profiles/company/162710-29)
The September 2018 Form D filing identifies Ketan Mehta as executive officer and director, Peter Ciano as executive officer, and Smita Mehta as director.[1](https://www.sec.gov/Archives/edgar/data/1754826/0001754826-18-000003.txt) At the time of the NextWave acquisition, Barry K. Herman served as Tris's Chief Medical Officer.[7](https://www.biospace.com/tris-pharma-expands-adhd-portfolio-with-acquisition-of-nextwave-pharmaceuticals)
## Products, technology and dosage-form platform
Tris's marketed ADHD line spans both major stimulant classes. DYANAVEL XR is an amphetamine; Quillivant XR and QuilliChew ER are methylphenidate hydrochloride products. All three are central nervous system stimulants approved for the treatment of ADHD in people 6 years and older.[5](https://www.trisadhd.com/) DYANAVEL XR, launched in 2016, was described as the first liquid amphetamine for children 6 years and older with ADHD.[7](https://www.biospace.com/tris-pharma-expands-adhd-portfolio-with-acquisition-of-nextwave-pharmaceuticals)
The company's core technology is LiquiXR, a proprietary extended-release liquid platform. Quillivant XR, the first marketed extended-release oral liquid methylphenidate, and QuilliChew ER, the first extended-release methylphenidate chewable tablet, were both developed on it.[7](https://www.biospace.com/tris-pharma-expands-adhd-portfolio-with-acquisition-of-nextwave-pharmaceuticals) The company states that its liquid and tablet formulations are designed to release medication gradually over time for ADHD symptom control through the day, an alternative to standard immediate-release pills that require multiple daily doses.[5](https://www.trisadhd.com/)
Alongside the branded business, Tris sells, markets, and distributes generic pharmaceutical products. In August 2019 it signed a license and commercial supply agreement with Intellipharmaceutics Corp for generic quetiapine extended-release tablets (ANDA #A202939), the therapeutic equivalent of Seroquel XR, in 50, 150, 200, 300, and 400 mg strengths, with Intellipharmaceutics manufacturing the product for Tris to sell.[4](https://www.sec.gov/Archives/edgar/data/1474835/000165495420003539/ex450.htm)
## Funding and investors
A Form D dated September 21, 2018 reports total amount sold of $125,000,000 against a $125,000,000 offering, with $42,461,745 sold to non-accredited investors.[1](https://www.sec.gov/Archives/edgar/data/1754826/0001754826-18-000003.txt)
Directory data also records a $5.27 million [Paycheck Protection Program](https://www.edgepedia.org/paycheck-protection-program) debt tranche completed April 13, 2020; this figure comes from a directory profile and is unverified by a primary document.[6](https://pitchbook.com/profiles/company/162710-29)
## Acquisitions and portfolio
Tris acquired NextWave Pharmaceuticals, a wholly owned subsidiary of Pfizer, bringing Quillivant XR and QuilliChew ER in-house. The two products had been co-developed by NextWave and Tris using the LiquiXR platform; Pfizer had acquired NextWave in 2012, and Tris had continued to manufacture both products for Pfizer after that.[7](https://www.biospace.com/tris-pharma-expands-adhd-portfolio-with-acquisition-of-nextwave-pharmaceuticals) The acquisition gave Tris marketed ADHD products in both the amphetamine and methylphenidate classes.[7](https://www.biospace.com/tris-pharma-expands-adhd-portfolio-with-acquisition-of-nextwave-pharmaceuticals)
## Business, traction and scale
Tris describes itself as an innovation-driven biopharmaceutical commercial-stage company applying drug development capabilities and proprietary technologies to ADHD, pain, and disorders of the central nervous system, and says it markets a portfolio of ADHD products while developing a pipeline of near-term drug candidates.[2](https://www.globenewswire.com/news-release/2026/07/09/3324711/0/en/Tris-Pharma-Launches-Adneuris-Therapeutics-to-Advance-a-New-Era-in-Pain-Medicine.html) Its commercial operations combine the branded ADHD franchise with the specialty generics distribution business documented in the Intellipharmaceutics agreement.[4](https://www.sec.gov/Archives/edgar/data/1474835/000165495420003539/ex450.htm)
A 2026 directory profile lists about 500 employees; like the founding year, this figure is directory data and unverified. No revenue figure or ADHD market-share estimate appears in the available record.[6](https://pitchbook.com/profiles/company/162710-29)
## Recent developments
In August 2025, Tris presented at the annual PAINWeek meeting in Las Vegas a novel mechanism of dual NOP/MOP (NMR) agonism for the treatment of moderate-to-severe acute pain, and encored positive Phase 3 data, according to the company's announcement.[8](https://www.businesswire.com/news/home/20250828170321/en/Tris-Pharma-Showcases-a-Novel-Mechanism-of-Dual-NOPMOP-NMR-Agonism-for-the-Treatment-of-Moderate-to-Severe-Acute-Pain-and-Encores-Positive-Phase-3-Data-at-2025-Annual-PAINWeek-Meeting-in-Las-Vegas) On July 9, 2026, the company announced the launch of Adneuris Therapeutics, a subsidiary created to advance its pain-medicine programs.[2](https://www.globenewswire.com/news-release/2026/07/09/3324711/0/en/Tris-Pharma-Launches-Adneuris-Therapeutics-to-Advance-a-New-Era-in-Pain-Medicine.html) These moves mark a strategic expansion beyond ADHD into pain medicine.
## References
1. [SEC Form D filing, Tris Pharma, Inc. (CIK 0001754826), filed September 2018](https://www.sec.gov/Archives/edgar/data/1754826/0001754826-18-000003.txt)
2. [Tris Pharma Launches Adneuris Therapeutics to Advance a New Era in Pain Medicine, GlobeNewswire, July 9, 2026](https://www.globenewswire.com/news-release/2026/07/09/3324711/0/en/Tris-Pharma-Launches-Adneuris-Therapeutics-to-Advance-a-New-Era-in-Pain-Medicine.html)
3. [Meet our leadership team | Tris Pharma](https://staging.trispharma.com/who-we-are/leadership/)
4. [License and Commercial Supply Agreement between Tris Pharma, Inc. and Intellipharmaceutics Corp (August 15, 2019), filed with SEC](https://www.sec.gov/Archives/edgar/data/1474835/000165495420003539/ex450.htm)
5. [ADHD Treatment - Children, Adolescents, & Adults | Tris Pharma](https://www.trisadhd.com/)
6. [Tris Pharma 2026 Company Profile, PitchBook (directory data)](https://pitchbook.com/profiles/company/162710-29)
7. [Tris Pharma Expands ADHD Portfolio with Acquisition of NextWave Pharmaceuticals, BioSpace](https://www.biospace.com/tris-pharma-expands-adhd-portfolio-with-acquisition-of-nextwave-pharmaceuticals)
8. [Tris Pharma Showcases a Novel Mechanism of Dual-NOP/MOP (NMR) Agonism at 2025 Annual PAINWeek Meeting, Business Wire, August 2025](https://www.businesswire.com/news/home/20250828170321/en/Tris-Pharma-Showcases-a-Novel-Mechanism-of-Dual-NOPMOP-NMR-Agonism-for-the-Treatment-of-Moderate-to-Severe-Acute-Pain-and-Encores-Positive-Phase-3-Data-at-2025-Annual-PAINWeek-Meeting-in-Las-Vegas)
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups › Small-molecule and chemical drug developers › Neuroscience and psychiatric drug developers*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license